Presented abstracts Under former U.S. Xeloda tissues. And 15 colorectal cancer abstracts highlight Xeloda as the cornerstone of combination treatment. The remaining Xeloda abstracts are also ex – U. Or sponsored by non – Roche company.
A U.S. Abstract to be published in the 2008 ASCO Proceedings I, compares the preclinical efficacy of an experimental, seven-days-on/seven-days-off Xeloda regimen versus the current standard dosage of Xeloda fourteen-days-on/seven-days-off in colorectal cancer. Findings from this study appeared in improved inhibition of tumor growth with the 7-on/7-off Xeloda regimen indicated; findings support clinical trials of this therapy in patients with colorectal cancer.[ See 2008 ASCO Proceedings I – An alternative preclinical therapy with capecitabine monotherapy & combination activity in a colorectal cancer xenograft model increased. ]. Read More